Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: Results in twenty-nine patients

Zackheim, Herschel S.; Kashani‐Sabet, Mohammed; Hwang, Sam T.

doi:10.1016/s0190-9622(96)80062-4

Cited by 134 publications

(64 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…32 Methotrexate has been tested for the same indication in 4 studies. [33][34][35][36] The best response rates were obtained in erythrodermic CTCL (58% 33 and 76% 34 ) and the worst ones in T3 disease. Gemcitabine has been evaluated in 2 studies in the treatment of advanced or refractory CTCL and showed response rates of 70% 37 and 75%.…”

Section: Commentmentioning

confidence: 95%

Prospective Multicenter Study of Pegylated Liposomal Doxorubicin Treatment in Patients With Advanced or Refractory Mycosis Fungoides or Sézary Syndrome

Quéreux

Marques²,

Nguyen³

et al. 2008

Arch Dermatol

View full text Add to dashboard Cite

show abstract

Section: Commentmentioning

confidence: 95%

Prospective Multicenter Study of Pegylated Liposomal Doxorubicin Treatment in Patients With Advanced or Refractory Mycosis Fungoides or Sézary Syndrome

Quéreux

Marques²,

Nguyen³

et al. 2008

Arch Dermatol

View full text Add to dashboard Cite

show abstract

“…In a retrospective study of 29 patients with erythrodermic CTCL, Zackheim and colleagues observed a CR rate of 41% and a PR rate of 17%, for a total ORR of 58% following MTX treatment. 124 Median TTF was 31 months. In addition, McDonald and Bertino reported that 7 of the 11 patients with stage II-III MF achieved a CR in their study described above.…”

Section: Retinoids Plus Puva Thomsen and Colleagues Re-mentioning

confidence: 99%

EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome

Trautinger

Knobler

Willemze

et al. 2006

European Journal of Cancer

388

308

View full text Add to dashboard Cite

“…For example, overall response rates of 58-76% (and 41% complete response rate) have been observed in patients with MF/SS treated with low-dose, oral methotrexate [336][337][338][339]. In contrast, for patients with an adequate performance status, single-agent gemcitabine [340][341][342][343][344], pegylated liposomal doxorubicin [345][346][347][348] and pentostatin [349][350][351][352][353][354][355] are frequently utilized (Table VI).…”

Section: Systemic Chemotherapymentioning

confidence: 99%

Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

Wilcox

2011

American J Hematol

View full text Add to dashboard Cite

Disease overview: Cutaneous T‐cell lymphomas are a heterogenous group of T‐cell lymphoproliferative disorders involving the skin, the majority of which may be classified as Mycosis fungoides (MF) or Sézary syndrome (SS).Diagnosis: The diagnosis of MF or SS requires the integration of clinical and histopathologic data.Risk‐adapted therapy: Tumor, node, metastasis, and blood (TNMB) staging remains the most important prognostic factor in MF/SS and forms the basis for a “risk‐adapted,” multidisciplinary approach to treatment. For patients with disease limited to the skin, expectant management or skin‐directed therapies is preferred, as both disease‐specific and overall survival for these patients is favorable. In contrast, patients with advanced‐stage disease with significant nodal, visceral, or blood involvement are generally approached with biologic‐response modifiers, denileukin diftitox, and histone deacetylase inhibitors before escalating therapy to include systemic, single‐agent chemotherapy. Multiagent chemotherapy may be used for those patients with extensive visceral involvement requiring rapid disease control. In highly‐selected patients with disease refractory to standard treatments, allogeneic stem‐cell transplantation may be considered. Am. J. Hematol., 2011. © 2011 Wiley‐Liss, Inc.

show abstract

Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: Results in twenty-nine patients

Cited by 134 publications

References 13 publications

Prospective Multicenter Study of Pegylated Liposomal Doxorubicin Treatment in Patients With Advanced or Refractory Mycosis Fungoides or Sézary Syndrome

Prospective Multicenter Study of Pegylated Liposomal Doxorubicin Treatment in Patients With Advanced or Refractory Mycosis Fungoides or Sézary Syndrome

EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome

Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

Contact Info

Product

Resources

About